Physician

Bradley Mark King, MD, MPH

According to 2025 Medicare claims, Bradley King, MD, MPH (NPI: 1043504152) practices ophthalmology in the Burlington, NC market, with the plurality of this provider's patient population coming from Alamance, NC. This provider's primary affiliated billing organization is ALAMANCE EYE CARE, PA (NPI: 1184641524; TIN: 56-1973223) and primary practice location at 27215-9714. King is affiliated with the Triad HealthCare Network, LLC. (ACO ID: D0209), participating under the REACH model.

King's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 553 traditional Medicare patients, billed 2,834 HCPCS/CPT codes, and received $208,697 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,985 prescription claims across 401 beneficiaries totaling $155,574 in drug costs, led by Restasis (Cyclosporine). 2022 DME data shows 29 claims. Open Payments data shows 22 records totaling $877. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $29,217 to $155,574. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	550	1,730	$200,812
2018	785	2,845	$312,179
2019	730	2,772	$278,171
2020	589	1,795	$205,547
2021	638	1,991	$214,461
2022	671	1,999	$191,239
2023	566	2,229	$191,111
2024	553	2,834	$208,697

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	103	317	$29,217
2016	58	212	$23,013
2017	178	355	$31,526
2018	425	1,236	$105,984
2019	426	2,316	$186,691
2020	407	2,152	$184,562
2021	370	2,004	$172,887
2022	401	2,057	$278,880
2023	383	2,018	$165,885
2024	401	1,985	$155,574

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	26	26	$2,053
2019	41	41	$3,079
2020	31	31	$2,191
2021	27	30	$2,355
2022	28	29	$1,992
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	169	$83
92014	Established patient complete exam of visual system	323	348	$75
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	88	114	$64
92083	Exam of visual field with extended testing	102	109	$43
92134	Imaging of retina	130	240	$27

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Restasis	Cyclosporine	33	1,620	$33,586
Rocklatan	Netarsudil Mesylat/Latanoprost	60	1,510	$20,458
Lumigan	Bimatoprost	45	1,570	$16,089
Xiidra	Lifitegrast	18	660	$14,923
Rhopressa	Netarsudil Mesylate	28	826	$10,184

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$877	BIOTISSUE HOLDINGS INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bradley Mark King, MD, MPH?

Tedicare shows public-source Medicare data for Bradley Mark King, MD, MPH (NPI 1043504152), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bradley Mark King, MD, MPH have ACO affiliation data?

Bradley Mark King, MD, MPH is shown with ACO affiliation data for Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to Bradley Mark King, MD, MPH?

Bradley Mark King, MD, MPH is linked to ALAMANCE EYE CARE, PA (billing NPI 1184641524) in the available physician profile data.

Does Bradley Mark King, MD, MPH have Open Payments data?

Bradley Mark King, MD, MPH has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.